Skip to main content
Health Catalyst, Inc. (HCAT)
Computer Software and Services Information Technology
Stock AI

Health Catalyst Reports Fourth Quarter and Year End 2025 Results

Last updated: March 12, 2026
Taurigo

Health Catalyst, Inc. (Nasdaq: HCAT), a prominent provider of data and analytics technology and services tailored for healthcare organizations, has released its financial results for the fourth quarter and fiscal year ending December 31, 2025. The report highlights both the challenges and opportunities that the company faces as it enters 2026.

1. 2025 Performance Summary

Ben Albert, CEO of Health Catalyst, expressed optimism regarding the company's performance, stating, “We closed 2025 with solid performance across our business, including total revenue of $311.1 million and Adjusted EBITDA of $41.4 million.” The results demonstrate a commitment to building on the company’s foundational strengths, while also acknowledging areas for improvement.

Key Financial Highlights

Fourth Quarter Results

  • Total Revenue: $74.7 million, a decline of 6% from $79.6 million in the same quarter of 2024.
  • Gross Profit: $31.4 million, marking a 10% increase compared to $28.6 million in Q4 2024.
  • Gross Margin: Increased to 42.0% from 35.9% year-over-year.
  • Net Loss: The company reported a substantial net loss of $91.0 million, a significant increase from a loss of $20.7 million in Q4 2024.

Full Year Results

  • Total Revenue: Reached $311.1 million, reflecting a modest 1% increase from $306.6 million in 2024.
  • Gross Profit: Improved to $120.4 million from $114.5 million in the previous year, a growth of 5%.
  • Gross Margin: Enhanced slightly to 38.7% from 37.3% year-over-year.
  • Net Loss: The annual net loss ballooned to $178.0 million, significantly higher than the $69.5 million loss reported in 2024.

2. Strategic Focus for 2026

Looking forward, Albert emphasized the company’s commitment to addressing its challenges with a clear plan and disciplined execution. He stated, “My priority is to build on these strengths, address our challenges with clarity and discipline, and move the company forward with a renewed sense of focus and execution.” This statement underlines Health Catalyst's intent to leverage its extensive experience with improvement projects and validated financial impact to create substantial value for both clients and shareholders.

3. Conclusion

Health Catalyst's financial results for 2025 paint a picture of a company that is navigating a complex landscape in the healthcare technology sector. While facing significant net losses, the company has shown resilience through increased gross profit and margin improvements. As Health Catalyst prepares for 2026, stakeholders will be keenly watching how the company leverages its strengths while addressing its operational challenges to enhance shareholder value and client satisfaction in the future.

You may also be interested in:
Copyright ©2026 Taurigo GmbH. All rights reserved.Taurigo GmbH provides no investment advice. Any analyses, research, ideas, prices, or other information contained on this website are provided as general market information for educational and entertainment purposes only, and do not constitute investment advice. We assume no responsibility for the accuracy, completeness or timeliness of any financial information contained on this site. In particular, we do not constitute an invitation to buy, sell or hold securities or other financial products. We shall not be liable for any loss or damage, including without limitation loss of profits, arising directly or indirectly from use of or reliance on the provided information. Before making any investment decision, you should consider whether it is suitable for your situation and obtain appropriate financial, tax and legal advice.